Will Mounjaro Be Approved for Weight Loss Soon?

Last reviewed: July 10, 2026

Last updated: July 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, the active ingredient in Mounjaro, has demonstrated remarkable weight loss results in clinical trials, with some participants losing up to 22% of their body weight. However, the FDA has not yet approved Mounjaro specifically for weight management—only for blood sugar control in type 2 diabetes. Understanding the current regulatory landscape and your access options matters for your health decisions.

Mounjaro's FDA Approval Status for Weight Loss

Mounjaro received FDA approval in 2022 exclusively for treating type 2 diabetes in adults. The manufacturer has not yet submitted a separate New Drug Application (NDA) for weight loss indication, meaning regulatory approval for that use remains pending. Unlike semaglutide, which has both Ozempic (diabetes) and Wegovy (weight loss) approved formulations, Mounjaro currently exists in only one FDA-approved context.

The pharmaceutical company has conducted the SURMOUNT clinical trial series, which evaluated tirzepatide's weight loss effectiveness across different patient populations. These trials showed consistently strong results, with participants receiving tirzepatide losing significantly more weight than those on placebo. However, clinical trial success does not automatically translate to FDA approval—the company must formally request this indication and work through the review process.

Tirzepatide Weight Loss Clinical Trial Results

The SURMOUNT-1 trial enrolled over 2,500 adults with obesity and showed that tirzepatide 15 mg produced an average weight loss of 22.5% of baseline body weight over 72 weeks. The highest dose tested (15 mg) resulted in even greater reductions, demonstrating a dose-response relationship. These results exceeded outcomes observed in comparable semaglutide trials, positioning tirzepatide as a potentially more potent GLP-1 receptor agonist combined with a GIP receptor agonist.

SURMOUNT-2 specifically evaluated tirzepatide in people with type 2 diabetes, showing average weight losses ranging from 6% to 20% depending on dose. Participants also experienced improvements in blood sugar control and cardiovascular risk factors. SURMOUNT-4 examined longer-term outcomes, revealing that weight loss was largely maintained during the maintenance phase when patients continued treatment.

When to Expect Mounjaro Weight Loss Approval

As of now, no official timeline has been announced for FDA approval of Mounjaro for weight loss. The manufacturer would need to submit a supplemental NDA and work through FDA review processes, which typically take several months to over a year depending on the review pathway chosen. Given the strong trial data already in the public domain, regulatory approval is considered probable by many industry analysts, but 'probable' is not the same as confirmed or imminent.

Market dynamics suggest that formal approval could occur within the next 12-24 months, though this estimate is speculative. Several other tirzepatide formulations and dosing regimens are also under development, which may further delay or accelerate approval timelines. Patients seeking tirzepatide for weight loss today do not need to wait for formal approval to access the medication through other legally sanctioned pathways.

How PlexusDx Tirzepatide Works Right Now

PlexusDx partners with licensed 503A compounding pharmacies to provide compounded tirzepatide injection, available immediately without requiring an FDA weight loss indication. Compounded tirzepatide starts at $289 per month across all commitment tiers—your dose may need to go up, but your price won't. This approach gives patients access to the medication today rather than waiting for future regulatory changes.

The compounded formulation delivers the same active ingredient as Mounjaro, prepared in a licensed pharmacy setting. PlexusDx serves all 50 states with no insurance requirement, no membership fees, and HSA/FSA eligibility. Patients can also add the Precision Peptide Genetic Test for $99 after their first month to identify which of the 14 peptide pathways they respond to most strongly, personalizing their treatment strategy.

Tirzepatide vs. Semaglutide: What's the Difference?

Tirzepatide activates two receptors—GLP-1 and GIP—whereas semaglutide activates only the GLP-1 receptor. This dual-receptor mechanism may explain tirzepatide's stronger weight loss results in head-to-head comparisons. Clinical trials suggest tirzepatide users lose approximately 3-5% more body weight than semaglutide users at comparable timepoints, though individual responses vary significantly.

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Your Options While Waiting for Mounjaro Approval

Waiting for FDA approval is one choice, but it delays access to proven treatment for months or longer. Compounded tirzepatide through PlexusDx offers an alternative: you can begin treatment now, track your results, and adjust your approach as needed. Many patients find that starting immediately produces better long-term outcomes than delaying treatment while regulatory decisions proceed.

PlexusDx also offers compounded semaglutide injection starting at $189/mo (or $149/mo on the 6-month plan), the GLP-Squared dual compound at $289/mo (or $249/mo on the 3-month plan), and the Microdose GLP-1 Protocol at $129/month for patients exploring lower-dose options first. Each product is formulated by licensed 503A compounding pharmacies, ensuring quality and consistency. Your healthcare provider can help determine which option aligns with your medical history, goals, and budget.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is tirzepatide FDA-approved for weight loss right now?

No. Tirzepatide (Mounjaro) is currently FDA-approved only for type 2 diabetes management. The weight loss indication remains under regulatory consideration, though clinical trial data is strong. PlexusDx provides compounded tirzepatide through licensed pharmacies, offering immediate access while approval decisions continue.

How much weight do people lose on tirzepatide in clinical trials?

In the SURMOUNT trials, participants lost an average of 22.5% of baseline body weight with tirzepatide 15 mg over 72 weeks. The highest doses tested produced even greater losses. Results exceeded those observed in comparable semaglutide trials, though individual outcomes vary based on genetics, lifestyle, and adherence.

Why should I consider compounded tirzepatide instead of waiting for Mounjaro approval?

Waiting adds months or more before you can start treatment. PlexusDx compounded tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan) and is available now through all 50 states. Your dose may increase over time, but your monthly price remains flat, and you can begin seeing results immediately rather than delaying treatment during the approval process.

Are compounded medications as safe as FDA-approved drugs?

PlexusDx partners exclusively with licensed 503A compounding pharmacies, which operate under strict FDA oversight, state pharmacy board regulations, and USP (United States Pharmacopeia) standards. These pharmacies follow rigorous quality control procedures. Compounded medications are not FDA-approved as products, but the ingredient and manufacturing process meet safety benchmarks established for patient care.

How does the Precision Peptide Genetic Test help with tirzepatide treatment?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Can I use HSA or FSA funds for PlexusDx tirzepatide?

Yes. PlexusDx compounded tirzepatide injection is HSA/FSA eligible, making it more affordable for eligible participants. There is no membership fee, and no insurance is required. PlexusDx serves all 50 states with transparent, flat monthly pricing across all commitment tiers.

Related Reading

• Mounjaro For Weight Loss 2
• Weight Loss Mounjaro
• Mounjaro Weight Loss By Week
• Weight Loss Injections Mounjaro

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.